LOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

LOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer.

On December22, 2017, David Bonita, M. D. advised the Board of Directors of Loxo Oncology,Inc. (“Loxo Oncology”) that he would resign as a ClassII independent director of Loxo Oncology and as a member of the audit and compensation committees of the board of directors, effective immediately. Dr.Bonita’s resignationis not the result of any disagreement with Loxo Oncology on any matter relating to its operations, policies or practices. Following Dr.Bonita’s resignation, Steven Elms was appointed to the audit committee and Steve Harr, M.D., was appointed to the compensation committee.


About LOXO ONCOLOGY,INC. (NASDAQ:LOXO)

Loxo Oncology, Inc. is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer. Its pipeline includes LOXO-101, LOXO-195, Rearranged During Transfection (RET) Program and Fibroblast Growth Factor Receptor (FGFR) program. LOXO-101 is a selective inhibitor of tropomyosin receptor kinases (TRK) for the treatment of patients with soft tissue sarcoma. LOXO-195 is a selective TRK inhibitor capable of addressing potential mechanisms of acquired resistance that may emerge in patients receiving LOXO-101 or multikinase inhibitors with anti-TRK activity. It has designed a series of RET inhibitors that optimize on-target potency for RET gene fusions, mutations and clinically-identified resistance mutations. It is designing FGFR1-sparing FGFR inhibitor.